TB/Non-TB Mycobacterial Infections
M-A | Assessing the diagnostic performance of new commercial IGRAs for Mycobacterium tuberculosis infection
24 Jan, 2023 | 14:25h | UTC
Commentary on Twitter
Assessing the diagnostic performance of new commercial IGRAs for Mycobacterium tuberculosis infection: a systematic review and meta-analysis
✅ Just Accepted
🔓 Open Access
🔗 https://t.co/8eO3ugZdfl pic.twitter.com/Fc2AjJyIw9— Clinical Infectious Diseases (@CIDJournal) January 23, 2023
Brief review and algorithm | Management of latent tuberculosis infection
23 Jan, 2023 | 13:35h | UTCManagement of Latent Tuberculosis Infection – JAMA (free for a limited period)
Consensus statement | Use of a 4-month treatment regimen for drug susceptible TB in children with uncomplicated disease
18 Jan, 2023 | 14:25h | UTC
WHO consolidated guidelines on tuberculosis | Drug-resistant tuberculosis treatment, 2022 update
12 Jan, 2023 | 13:30h | UTCSee also:
– WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment
RCT | A 24-week, all-oral regimen for rifampin-resistant tuberculosis
12 Jan, 2023 | 13:27h | UTCA 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis – New England Journal of Medicine
Commentary: Trial results show superiority of shorter, all-oral treatment for drug-resistant TB – CIDRAP
Collection of Cochrane evidence on diagnosing tuberculosis.
1 Dec, 2022 | 13:56h | UTCCollection of Cochrane evidence on diagnosing tuberculosis – Cochrane Library
WHO Global tuberculosis report 2022.
29 Nov, 2022 | 14:25h | UTCGlobal tuberculosis report 2022 – World Health Organization
News Release: Tuberculosis deaths and disease increase during the COVID-19 pandemic – World Health Organization
Video Summary: WHO Global Tuberculosis Report 2022: Key findings and messages – World Health Organization
Commentary on Twitter (thread – click for more)
🆕 WHO 2022 Global TB report 🧵
For the first time in many years, an increase has been reported in the number of people falling ill with #tuberculosis (TB) and drug-resistant TB.
📌 https://t.co/AvVFJ6j1E5 pic.twitter.com/dPywHXZ6ND
— World Health Organization (WHO) (@WHO) October 27, 2022
RCT | Evaluation of two short, standardized regimens for the treatment of rifampicin-resistant tuberculosis.
15 Nov, 2022 | 12:57h | UTCCommentary:
Shorter treatment effective for drug-resistant tuberculosis – University College London
Shorter Treatment Regimen for Drug-Resistant TB is More Effective – Health Policy Watch
RCT | Efficacy of 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide for treatment of fluoroquinolone-sensitive MDR-TB.
9 Nov, 2022 | 12:11h | UTC9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea – The Lancet (link to abstract – $ for full-text)
RCT | A digital medication event reminder may improve quality of life and reduce costs in patients with tuberculosis.
1 Nov, 2022 | 11:48h | UTCCommentaries:
Digital Medication Device Improves Quality of Life, Reduces Costs for TB Patients – HCP Live
Digital Medication Monitor Linked to Better HRQOL, Lower Costs for Tuberculosis – AJMC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1570442333686042628
Systematic Review | Global frequency and clinical features of stroke in patients with tuberculous meningitis.
6 Sep, 2022 | 14:19h | UTC
RCT | Bedaquiline–Pretomanid–Linezolid regimens for drug-resistant tuberculosis.
2 Sep, 2022 | 13:16h | UTCBedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Three drug regimen with Linezolid 600 mg tied to better outcomes in drug-resistant TB – Medical Dialogues
Perspective | Ending tuberculosis in a post-COVID-19 world: a person-centered, equity-oriented approach.
19 Aug, 2022 | 16:02h | UTC
Commentary on Twitter
New personal view: Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach https://t.co/jLFPLWc39w pic.twitter.com/TBlSYlp4P0
— The Lancet Infectious Diseases (@TheLancetInfDis) August 11, 2022
Perspective | Epidemiological approach to ending tuberculosis in high-burden countries.
19 Aug, 2022 | 15:59h | UTCEpidemiological approach to ending tuberculosis in high-burden countries – The Lancet
Commentary on Twitter
"We need to make concerted efforts now to finally eliminate #tuberculosis everywhere."@Marks1Guy and colleagues on an epidemiological approach in high-burden countries: https://t.co/MXviPYdp2q pic.twitter.com/CXt1BOgQW8
— The Lancet (@TheLancet) August 6, 2022
M-A | Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course.
15 Aug, 2022 | 12:21h | UTCInvited Commentary: Infant BCG vaccination is beneficial, but not sufficient – The Lancet Global Health
News Release: BCG vaccine prevents tuberculosis in young children, but not adults – Boston University School of Public Health
Commentary from the author on Twitter (thread – click for more)
1/n Our new @LancetGH study investigating BCG vaccination in infancy and tuberculosis risk is out!
Link: https://t.co/Gu469QlnFh pic.twitter.com/yRIdb2I7Zr
— Leo Martinez (@LeoMarti_EpiTB) August 9, 2022
M-A | Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021.
3 Aug, 2022 | 14:04h | UTC
M-A | Lung cancer occurrence after an episode of tuberculosis.
29 Jul, 2022 | 12:28h | UTC
Review | Tuberculosis in cirrhosis – A diagnostic and management conundrum.
7 Jul, 2022 | 12:18h | UTC
M-A: Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis.
15 Jun, 2022 | 10:47h | UTC
Commentary on Twitter
This meta-analysis of pregnant patients treated for multi-drug-resistant tuberculosis (MDR-TB) found 73% treatment success and 73% favorable pregnancy outcomes, with adverse events (incl liver/kidney impairment, hearing loss) in more than half of patients. https://t.co/Mx5RLiwhU9
— JAMA Network Open (@JAMANetworkOpen) June 10, 2022
Systematic Review: Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
25 May, 2022 | 10:46h | UTCSummary: Xpert MTB/XDR, a rapid test for resistance to tuberculosis drugs – Cochrane Library
Modeling Study: 20% of multi-drug resistant tuberculosis cases in children could be averted by household testing and treatment.
25 May, 2022 | 10:44h | UTCInvited Commentary: Investing in drug-resistant tuberculosis household contact management and preventive treatment – The Lancet Global Health
WHO calls for shorter drug course for resistant TB.
4 May, 2022 | 11:08h | UTCWHO calls for shorter drug course for resistant TB – CIDRAP
Rapid communication: Key changes to the treatment of drug-resistant tuberculosis – World Health Organization
Review: Anti-tuberculosis treatment strategies and drug development: challenges and priorities.
1 May, 2022 | 23:23h | UTCAnti-tuberculosis treatment strategies and drug development: challenges and priorities – Nature Reviews Microbiology (if the link is paywalled, try this one)
News Release: A major update on global tuberculosis fight – Hackensack Meridian Health
Commentary on Twitter
Anti-tuberculosis treatment strategies and drug development: challenges and prioritieshttps://t.co/nZlcEwTDLP
In this Review, Dartois and Rubin explore challenges and priorities for anti-tuberculosis treatment strategies and drug development.@vdartois1 pic.twitter.com/t6RQoaFb8C
— Nature Reviews Microbiology (@NatureRevMicro) April 27, 2022
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.
27 Apr, 2022 | 07:52h | UTC
Drug resistant TB – latest developments in epidemiology, diagnostics and management.
13 Apr, 2022 | 10:09h | UTCRelated:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment
Canadian Tuberculosis Standards – 8th Edition.
Guideline: Treatment of Drug-Resistant Tuberculosis
The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis
Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives